Evaluation of the presence of Th1 response through T-bet and IFN-gamma immunohistochemical expression in lower lip and oral tongue squamous cell carcinomas

被引:0
|
作者
Rodrigues, Rodrigo Rodrigues [1 ]
Freitas, Valeria Souza [2 ]
Alves, Pollianna Muniz [3 ]
Freitas, Roseana de Almeida [1 ]
de Souza, Lelia Batista [1 ]
Santos, Pedro Paulo de Andrade [4 ,5 ]
机构
[1] Fed Univ Rio Grande Norte UFRN, Dept Oral Pathol, Natal, RN, Brazil
[2] State Univ Feira De Santana UEFS, Dept Dent, Feira De Santana, BA, Brazil
[3] State Univ Paraiba UEPB, Dept Dent, Campina Grande, PB, Brazil
[4] Fed Univ Rio Grande Norte UFRN, Dept Morphol, Natal, RN, Brazil
[5] Campus Univ, BR-59078900 Natal, RN, Brazil
关键词
Oral cancer; T; -bet; Interferon; Tongue neoplasms; Lip neoplasms; INTERFERON-GAMMA; SURVIVAL; CANCER;
D O I
10.1016/j.prp.2023.155010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
<bold>Introduction: </bold>Evaluate the immunohistochemical expression of T-bet and IFN-gamma in lower lip (LLSCC) and oral tongue squamous cell carcinoma (OTSCC), verifying the presence of Th1 responses in lesions with different clinical conditions. <bold>Methods and materials: </bold>Thirty OTSCC and 30 LLSCC were analyzed by immunohistochemistry. T-bet was quantitatively assessed by parenchyma cell and stroma quantification, and IFN-gamma was semi-quantitatively analyzed: 1:0-25%; 2:26-50%; 3:51-75%; 4:> 75% immunopositive cells. Histological differentiation degrees were categorized as well differentiated (WD), moderately differentiated (MD), or poorly differentiated (PD). <bold>Results: </bold>OTSCC presented the highest number of T-bet(+), parenchyma (p: 0.006), stroma (p: 0.156), parenchyma/stroma (p: 0.015), with no relationship to histological malignancy grade. IFN-gamma higher concentrations in LLSCC were detected in parenchyma, stroma and in parenchyma/stroma (p: 0.000), as well as greater immunoreactivity in WD and MD (p: 0.001). In OTSCC, a positive and statistically significant correlation was observed between T-bet(+) in parenchyma and IFN-gamma in stroma(r: 0.388; p: 0.034), in addition to a statistically significant positive correlation between T-bet in parenchyma compared to stroma(r: 0.411; p: 0.024) and for IFN-gamma in both parenchyma and stroma(r: 0.775; p: 0.000) in LLSCC. Higher T-bet(+) was observed in OTSCCs, although higher IFN-gamma was detected in LLSCCs. <bold>Conclusion: </bold>Thus, we suggest that, even though LLSCC presented lower T-bet(+), the favorable microenvironment in these lesions led to an expressive activation of IFN-gamma by T-bet(+), considerably acting on Th1 differentiation and in antitumor activity, which, admittedly, present less aggressive behavior, reinforcing once again the important role of this cytokine and its use in strategy to fight cancer.
引用
收藏
页数:7
相关论文
共 40 条
  • [21] Expression of TH1 and TH17 cytokines and transcription factors in multiple sclerosis patients: Does baseline T-Bet mRNA predict the response to interferon-beta treatment?
    Drulovic, Jelena
    Savic, Emina
    Pekmezovic, Tatjana
    Mesaros, Sarlota
    Stojsavjevic, Nebojsa
    Dujmovic-Basuroski, Irena
    Kostic, Jelena
    Vasic, Vladimir
    Stojkovic, Marija Mostarica
    Popadic, Dusan
    JOURNAL OF NEUROIMMUNOLOGY, 2009, 215 (1-2) : 90 - 95
  • [22] Differential Expression of Ly6C and T-bet Distinguish Effector and Memory Th1 CD4+ Cell Properties during Viral Infection
    Marshall, Heather D.
    Chandele, Anmol
    Jung, Yong Woo
    Meng, Hailong
    Poholek, Amanda C.
    Parish, Ian A.
    Rutishauser, Rachel
    Cui, Weiguo
    Kleinstein, Steven H.
    Craft, Joe
    Kaech, Susan M.
    IMMUNITY, 2011, 35 (04) : 633 - 646
  • [23] T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-γ expression
    Long, MX
    Slaiby, AM
    Hagymasi, AT
    Mihalyo, MA
    Lichtler, AC
    Reiner, SL
    Adler, AJ
    JOURNAL OF IMMUNOLOGY, 2006, 176 (02): : 1036 - 1045
  • [24] IL-2-mTORC1 signaling coordinates the STAT1/T-bet axis to ensure Th1 cell differentiation and anti-bacterial immune response in fish
    Ai, Kete
    Li, Kang
    Jiao, Xinying
    Zhang, Yu
    Li, Jiaqi
    Zhang, Qian
    Wei, Xiumei
    Yang, Jialong
    PLOS PATHOGENS, 2022, 18 (10)
  • [25] T-bet down-modulation in tolerized Th1 effector CD4 cells confers a TCR-distal signaling defect that selectively impairs IFN-γ expression.
    Long, MX
    Slaiby, AM
    Hagymasi, AT
    Mihalyo, MA
    Lichtler, AC
    Reiner, SL
    Adler, AJ
    BLOOD, 2005, 106 (11) : 928A - 928A
  • [26] Chronic Lymphocytic Leukemia Cells Express CD38 in Response to Th1 Cell-Derived IFN-γ by a T-bet-Dependent Mechanism
    Burgler, Simone
    Gimeno, Aleix
    Parente-Ribes, Anna
    Wang, Dong
    Os, Audun
    Devereux, Stephen
    Jebsen, Peter
    Bogen, Bjarne
    Tjonnfjord, Geir E.
    Munthe, Ludvig A.
    JOURNAL OF IMMUNOLOGY, 2015, 194 (02): : 827 - 835
  • [27] Immunohistochemical expression of vascular endothelial growth factor correlates with positive surgical margins and recurrence in T1 and T2 squamous cell carcinoma (SCC) of the lower lip
    Kyzas, PA
    Stefanou, D
    Agnantis, NJ
    ORAL ONCOLOGY, 2004, 40 (09) : 941 - 947
  • [28] VIRUS-INDUCED INTERFERON-ALPHA-BETA (IFN-ALPHA-BETA) PRODUCTION BY T-CELLS AND BY TH1 AND TH2 HELPER T-CELL CLONES - A STUDY OF THE IMMUNOREGULATORY ACTIONS OF IFN-GAMMA VERSUS IFN-ALPHA-BETA ON FUNCTIONS OF DIFFERENT T-CELL POPULATIONS
    KLIMPEL, GR
    INFANTE, AJ
    PATTERSON, J
    HESS, CB
    ASUNCION, M
    CELLULAR IMMUNOLOGY, 1990, 128 (02) : 603 - 618
  • [29] mRNA Quantification of T-bet, GATA-3, IFN-γ, and IL-4 Shows a Defective Th1 Immune Response in the Peripheral Blood from Rheumatoid Arthritis Patients: Link with Disease Activity
    Masanori Kawashima
    Pierre Miossec
    Journal of Clinical Immunology, 2005, 25 : 209 - 214
  • [30] mRNA quantification of T-bet, GATA-3, IFN-γ, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients:: Link with disease activity
    Kawashima, M
    Miossec, P
    JOURNAL OF CLINICAL IMMUNOLOGY, 2005, 25 (03) : 209 - 214